



UNITED STATES
NUCLEAR REGULATORY COMMISSION
WASHINGTON, D.C. 20555-0001

February 24, 2015

Mr. Robin DeLaBarre
Office of Nuclear Energy, Safety
& Security Affairs, Room 3320 HST
Bureau of International Security
& Nonproliferation
U.S. Department of State
2201 C Street, NW
Washington, DC 20520

Dear Mr. DeLaBarre:

Enclosed is an application (XMAT434), dated February 12, 2015, received by the U.S. Nuclear Regulatory Commission (NRC), from Concert Pharmaceuticals, Inc. for the export of up to 20,000 kilograms of heavy water (D₂O) over a five-year period to Carbogen Amcis AG in Switzerland for a non-nuclear end use in active pharmaceutical ingredient manufacturing.

Inasmuch as Executive Branch views are not required for exports of deuterium to Switzerland for a non-nuclear end-use, the NRC intends to issue the requested license after the required 30-day waiting period is complete and upon publication of notice in the Federal Register.

Sincerely,

Brooke G. Smith, Chief
Export Controls and Nonproliferation Branch
Office of International Programs

Enclosure:
Application Dated 2/12/2015
XMAT434 – Switzerland
Docket Number 11006190

cc w/enclosure:
H. Lane, NRC/NMSS
S. Aguilar, NRC/NMSS
P. Dessaulles, DOE/NMMSS
S. Clagett, DOC
O. Toigo, DHS/CBP

R. Goorevich, DOE/NNSA
K. Strangis, DOE/NNSA
J. Norles, DOE/NNSA
E. Sauls, DTRA